See more : Samsung Heavy Industries Co., Ltd. (010140.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Krystal Biotech, Inc. (KRYS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Krystal Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aruna Hotels Limited (ARUNAHTEL.BO) Income Statement Analysis – Financial Results
- Applus Services, S.A. (APLUF) Income Statement Analysis – Financial Results
- Tongyang Inc. (001529.KS) Income Statement Analysis – Financial Results
- Silver Bullet Data Services Group PLC (SBDS.L) Income Statement Analysis – Financial Results
- Host Hotels & Resorts, Inc. (HST) Income Statement Analysis – Financial Results
Krystal Biotech, Inc. (KRYS)
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.70M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Cost of Revenue | 3.09M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| Gross Profit | 47.61M | -4.05M | -2.77M | -1.85M | -974.00K | 886.00K | -23.00K | -2.00K |
| Gross Profit Ratio | 93.90% | 0.00% | 0.00% | 0.00% | 0.00% | 86.27% | 0.00% | 0.00% |
| Research & Development | 46.43M | 42.46M | 27.88M | 17.94M | 15.62M | 7.76M | 3.21M | 741.00K |
| General & Administrative | 0.00 | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 98.40M | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Other Expenses | 12.50M | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 157.33M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Cost & Expenses | 147.93M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Interest Income | 22.62M | 5.22M | 197.00K | 832.00K | 2.99M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 5.22M | 1.49M | 0.00 | 0.00 | 1.03M | 3.15M | 7.00K |
| Depreciation & Amortization | 5.01M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| EBITDA | 17.90M | -145.20M | -65.31M | -30.32M | -18.11M | -10.75M | -4.63M | -1.14M |
| EBITDA Ratio | 35.31% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.54% | 0.00% | 0.00% |
| Operating Income | -109.73M | -145.20M | -68.28M | -33.00M | -22.08M | -11.92M | -4.77M | -1.14M |
| Operating Income Ratio | -216.43% | 0.00% | 0.00% | 0.00% | 0.00% | -1,160.27% | 0.00% | 0.00% |
| Total Other Income/Expenses | 122.62M | 5.22M | -1.30M | 832.00K | 2.99M | 1.03M | -3.15M | -7.00K |
| Income Before Tax | 12.90M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Income Before Tax Ratio | 25.44% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| Income Tax Expense | 1.97M | 34.05M | 2.73M | 1.64M | 576.14K | -20.14K | 0.00 | 0.00 |
| Net Income | 10.93M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Net Income Ratio | 21.56% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| EPS | 0.40 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| EPS Diluted | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| Weighted Avg Shares Out | 27.15M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
| Weighted Avg Shares Out (Dil) | 27.75M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?
Krystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Source: https://incomestatements.info
Category: Stock Reports